49 results about "Multinucleate giant cell" patented technology

The reagent includes the sample pad, the binding pad, the cellulose nitrate film, the water uptake pad and the PVC back cover. The sample pad, the binding pad are adhered to the one end with PVC backcovered in sequence. The cellulose nitrate film is adhered to the middle. The water uptake pad is adhered to another end of the reagent. The binding pad is coated with the label of albumen A (or rabbit anti human IgG)-colloidal gold. The cellulose nitrate film is coated with the specificity surface film antigen of giant cells virus and chickens anti albumen A (or sheep anti rabbit IgG). The reagent features high specificity and sensitivity, simple and fast. The reagent is applicable to the detection in site within 30 minutes for the full testing procedure.

The invention provides a method for detecting pathogenic microorganisms by using a PCR (polymerase chain reaction) enzyme-linked double-cross method, belongs to the technical field of clinical medical microorganism detection, and particularly relates to a synchronous qualitative and quantitative detection method for various microorganisms. In the method, DNA (deoxyribonucleic acid) amplification, DNA hybridization and enzyme-linked immunosorbent assay reaction are used, a solid-phase surface enveloping technology is adopted, a specificity conservative segment is amplified, an amplified product is combined to a capturing probe and is adsorbed to a solid-phase surface, far-end hybridization of an enzyme-linked probe is carried out, and a quantitative color product is generated by specific antibody recognition and reaction of enzyme and a substrate. The detected pathogenic microorganisms comprise EB (Epstein Barr) viruses, giant cell and cell viruses, herpes simplex viruses 1 and herpes simplex viruses 2. Various microorganisms of a clinical sample are detected simultaneously, and four types of viruses are screened by a reaction. The method has the advantages that the time and the cost are saved, application is flexible, the repeatability, the stability, the sensitivity and the specificity are high, and the method is simple and is easy to implement. Moreover, the method is suitable for widely detecting pathogenic microorganisms and is particularly suitable for a basic medical institution.

The invention discloses a non-tumorigenic MDCK cell line used for amplifying influenza viruses and a screening method thereof. The cell line is MDCK-2B2 with an accession number of CCTCC 201323. The invention provides the non-tumorigenic MDCK-2B2 cell line and a subclone cell line thereof; and the cell line can grow into adherent cells, and/or has an epithelioid form and/or can support duplication of a variety of viruses, and is capable of amplifying viruses with high titers. The invention also provides the screening method for the non-tumorigenic cell line. The growth speed and morphologic changes of cells can be used to assist in determination of tumorigenicity; i.e., simple-pore cells with a slow growth speed have substantially reduced tumorigenicity, and occurrence of giant cells enables tumorigenicity to be substantially increased; during large-scale screening of non-tumorigenic cell lines, such an auxiliary determination method can shorten time and save cost.

The invention discloses an application of Lambda interferon in resisting human immunodeficiency virus. IFN-Lambda resisting HIV infection can inhibit the infection and replication of HIV-1 in human macrophage, which is presented by the following processes: (1) IFN-Lambda1/Lambda2 differentiates mature human macrophage through pretreatment, then HIV-1R5 type strain respectively infects the cells, a DMEM culture medium is used for washing and then a DMEM culture medium containing 10 percent of fetal calf serum is added for culture; and (2) after infection, the formed multinucleate giant cells of IFN-Lambda treatment group are rather less than those of a virus contrast group, and the HIV-1 reverse transcriptase and envelope protein P24 in culture supernatant fluid of the IFN-Lambda treatment group are detected to be rather less than that of the virus contrast group. After infection, the HIV-1RT in the culture supernatant fluid is respectively detected. The effect of inhibiting the HIV-1 is obvious after infection. The IFN-Lambda treatment group has obvious time and dose-effect relationship in inhibiting the activity of HIV-1RT after infection. The function of IFN-Lambda in resisting the HIV-1 is similar to that of other interferons and has the antivirus effect. The IFN-Lambda shows obvious effect of inhibiting the replication of virus as regards to the human macrophage before, in and after the infection of the HIV-1 virus.

The invention belongs to the field of bone marrow cell morphology detection, and particularly relates to a counting and analyzing method of an automatic bone marrow cell morphology detection system. According to the technical scheme, the counting and analyzing method of the automatic bone marrow cell morphology detection system comprises the following steps: S1, recognizing low-magnification images integrally, and searching and counting special cells and giant cells in the low-magnification images; and S2, randomly selecting a plurality of counting areas in the areas of the screened high-powerimages, and identifying and counting all kinds of cells in the areas; and S3, performing reference judgment on the counting result of each counting area. According to the invention, multi-point sampling is adopted, and then representative analysis is performed on the data of each sampling point, so that the data of each sampling point has reference. Then, all the data with the reference samplingpoints are subjected to weighted calculation, so that the statistical data is closer to a real value, and the final data is more accurate in pointing.

The invention discloses an IRES-mediated recombinant adenovirus vector and the recombinant adenovirus for co-expressing CTLA4Ig and CTLA4. The preparing method thereof comprises the steps: a CTLA4Ig gene, an IRES gene and a CTLA4 gene are inserted sequentially into the downstream of a giant cell virus promoter in a pAdTrack-CMV shuttle vector, a recombinant shuttle vector carrying the CTLA4Ig gene, the IRES gene and the CTLA4 gene is then obtained, and the recombinant shuttle vector is recombined in homologous with a virus backbone vector pAdeasy-1 to obtain the recombinant adenovirus vector for co-expressing the CTLA4Ig and the CTLA4; and the recombinant adenovirus expression vector transfects packaging cells (293 cells of human embryo kidney) to obtain recombinant adenovirus, and mammalian cells are infected by the recombinant adenovirus in vitro, thereby ensuring purpose cells with immunological suppression function. The recombinant adenovirus can play an important role in the medical field, especially in the organ transplanting field, thereby having extensive application prospect.

The invention relates to an acquired immune deficiency syndrome (AIDS) infected cell separator and belongs to the field of biomedicine. The AIDS infected cell separator is characterized in that a cell separator, through which a single blood cell and chemical components can pass, but a large-volume cell formed by combining two or more blood cells cannot pass, has pore diameter being 150 to 250 microns, 50 to 150 microns, 15 to 40 microns, 8 to 15 microns, 5 to 8 microns, 3 to 5 microns and 1 to 2 microns and is correspondingly calibrated as I-VII type, is prepared from a high-biocompatibility material; an HIV (human immunodeficiency virus) gp120 antibody and a CD4 antibody are prepared; gp120 on the surface of the HIV infected cell can be adhered to another CD4+ cell by itself or under the effects of the gp120 antibody or the CD4 antibody to form a large-volume multinuclear giant cell; the I-II type separators are selected to separate ultra-large volume fungi, spirillum and tumor cells; the III-VII type separators are selected to separate HIV infected large-volume multinuclear giant cells, multicellular polymers and CD4+ cells susceptible to HIV infection; the AIDS infected cells are separated and eliminated in extracorporeal circulation formed by the separator and other parts.

The invention discloses an AIDS biological cellular immunotherapy apparatus, and belongs to the field of medicine. The AIDS biological cellular immunotherapy apparatus is characterized in that blood and plasma separators, by which plasma, individual blood cells and multinuclear giant cells formed due to HIV parasitism are prepared; SV40LTag-pcDNA3.1 (-) and pLXSNneo-hTERT recons are constructed; combined transfection is conducted, so as to cause macrophage immortalization; the macrophage, after being subjected to amplification, is prepared in a cell cryopreservation solution until a cell concentration is 80%, and then, a purifier, which is made from a high polymer material, is poured with cells, wherein macrophage cell lines take an effect on phagocytizing HIV; the purifier and the blood and plasma separators constitute a key extracorporeal circulation device; when blood passes through the blood separator, the multinuclear giant cells which contain the HIV are filtered and removed, and subsequently, when plasma, which is separated by virtue of the plasma separator, passes through the purifier, the HIV in the plasma is phagocytized by the macrophage; and the purified plasma is mixed with the individual blood cells separated by virtue of the plasma separator, and then, the mixed plasma and individual blood cells are conveyed back, so that the purification treatment purpose of clearing the HIV inside and outside the blood cells is achieved.

A reagent kit of specificity IgG and its affine index detection is prepared by planting giant cell virus AD169 plant, herpes simplex virus I type SM-44 plant, herpes simplex II type G pland on diploid cell of human embryo lungs, planting nettle rash virus Gos plant, bowworm RH plant on Vero cell, obtaining antigen Via developing, encapsulating polystrene ELISA reaction plate after tiration and purification to be certain concentration as well as preparing specimen dilution liquid developer solution, concentration cleaning liquid and so on.

The invention discloses a method for effectively observing a tomato root knot giant cell paraffin section. The method studies three key factors affecting the effect of the tomato root knot giant cellparaffin section, and the tomato root knot giant cell paraffin section technology includes a new material-taking and embedding method and a section selection technology is established. The technologyobviously improves the working efficiency of the tomato root knot giant cell paraffin section, improves the section selection quality, and ensures the effect of the tomato root knot giant cell paraffin section. The method has the advantages of high practicality and clear technical parameters, can be used for developing a related paraffin section embedding die and a matched paraffin section specialtechnology, and can be widely promoted and applied.

The invention discloses an AIDS (Acquired Immune Deficiency Syndrome) blood purification therapeutic apparatus, comprising a blood and blood serum separator capable of separating blood serum, single blood cell from multinucleated giant cells formed by inquilinous HIV (Human Immunodeficiency Virus) and comprising a purifier including an HIV antibody capable of being combined with the HIV, a CD4+T cell line and a hybridoma macrophage cell line. When blood flows through the separator, the multinucleated giant cells containing the HIV are filtered out; when the separated blood serum flows through the purifier, the HIV is adsorbed and cleaned by a purification agent; the purified blood serum and the single blood cell separated by the separator are converged and then are conveyed back to a body, so that the AIDS blood purification therapeutic aim of cleaning the HIV in and out of the blood cells is realized.

The invention discloses an artificially synthesized cationic peptide (named as AIK) and applications thereof in preparing an anti-tumor drug. The amino acid sequence of the cationic peptide is shown as SEQ ID NO.1. A research shows that the AIK has an obvious inhibition effect on various solid tumor cells, especially leukemic cells, cells of pulmonary giant cell cancer and hepatoma ascites cells, the anti-tumor activity is possibly combined an anionic acceptor on the surface of tumor cells so as to induce the tumor cells to be subjected to apoptosis and necrosis, and the anti-tumor activity is higher than that of the anti-tumor peptide molecules reported by other researchers. More importantly, the artificially synthesized 25-peptide drug molecules have higher specificity on the tumor cells. After the anti-tumor drug is locally administrated by subcutaneous tumor-bearing mice, the subcutaneous growth of liver cancer cells H22 of the tumor-bearing mice can be obviously inhibited and toxic and side effects are lower than chemotherapeutic drugs amethopterin. The artificially synthesized cationic peptide can provide theoretical basis and experimental materials for further researching and developing polypeptide anti-tumor new drugs and small-size targeted anti-tumor new drugs.

An HIV (human immunodeficiency virus) immune purifier for the field of medical science is characterized in that a blood separator is prepared to filter multinuclear giant cells formed by lodging of HIV, a plasma separator is prepared to separate plasma and single blood cells, an HIV gp120 antibody and an HIVgp41 antibody capable of combining the HIV and HIV gp120 and gp41 antibodies capable of combining anti-goat Ig are prepared to serve as purifying agents distributed in agar gel, the agar gel is wrapped by high polymer materials to prepare the purifier, the purifier, the blood separator and the plasma separator jointly form critical components of an extracorporeal blood circulation device, the multinuclear giant cells containing the HIV are filtered when blood flows through the blood separator, the HIV is adsorbed and removed by the purifying agents when the plasma separated by the plasma separator flows through the purifier, and the purified plasma is converged with the single blood cells separated by the plasma separator and then returned into a body, so that HIV blood purification treatment of removing the HIV inside and outside the blood cells is achieved.

The invention discloses an application of p110 delta and an antibody of the p110 delta in specifically marking an early trophoblast giant cell (Parietal TGC, pTGC). The p110 delta is a segment of p110 delta; an amino acid sequence of the segment is as described as SEQIDNO.1. According to a record, a p110 delta antibody is used as a detection medium for specifically marking pTGC by using conventional technical methods such as an immunohistochemical method, an immunofluorescence method or a polymerase chain reaction (PCR) method; a marker is relatively simple and convenient; the detection time is greatly shortened; the marker is easy to identify, relatively high in success rate, relatively good in user acceptance and relatively convenient to use in clinic. In addition, compared with those of the nucleic acid of hybridization in situ, the observation index is in the protein level; the organism effect condition can be reflected relatively directly; the application range is relatively wide.

An AIDS blood plasma purifying therapeutic instrument in the medical science field comprises a blood separator, a blood plasma separator and a blood plasma purifier; the blood plasma separator can separate blood plasma from single blood corpuscles; the blood separator can filter multinuclear giant cells formed by lodging HIV; the blood plasma purifier can prepare and amplify infinite growing hybridomas macrophage strains with phagocytosis characteristic, the hybridomas macrophage strains are mixed in a cell frozen stock solution so as to enable cell concentration to reach 80%, and the purifier is made by pouring high-molecular material; the macrophage strains can swallow HIV; the purifier, the blood separator and the blood plasma separator can form a key external cycle system; when flood flows to pass the blood separator, the multinuclear giant cells containing HIV can be filtered; when the blood plasma separated by the blood plasma separator passes the purifier, containing HIV can be removed by a cleanser; the purified blood plasma can gather with single blood cells separated by the blood plasma separator, and can be returned, thus realizing purifying treatment purpose by removing HIV inside and outside blood cells.

The invention discloses a traditional Chinese medicine for treating haemorrhoids. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 25-35 parts of delavay pararuellia herb, 10-20 parts of desmodium microphyllum, 10-18 parts of chicken's-claw wind and 8-12 parts of hairyfruit croton leaves and roots. A corresponding preparation method is adopted. The traditional Chinese medicine provided by the invention has the functions of treating haemorrhoids and inhibiting cell proliferation of human giant cell lung cancer cells A549.

The invention relates to a method for treating giant cell tumor of bone. Specifically, the invention provides application of a CD44 inhibitor, and the CD44 inhibitor is used for preparing the medicine for treating the giant cell tumor of the bone. Experimental results of the invention show that, the SRGN can be used as a novel biological marker for predicting the giant cell tumor of the bone and is used for diagnosing, typing and/or treating the giant cell tumor of the bone. Besides, in the tissue of giant cell tumor of the bone, the fusiform stromal cells can secrete glycoprotein of SRGN and can interact with the CD44 receptor on the mononuclear cells, so that the mononuclear cells are promoted to be differentiated into multinuclear giant cells. Therefore, the CD44 can be used as a target for clinically treating the giant cell tumor of the bone.